Haftungsausschluss: Diese Website bündelt öffentlich verfügbare Daten aus offiziellen Quellen wie FDA, ClinicalTrials.gov, PubMed und SEC EDGAR nur zur allgemeinen Information. Sie stellt keine medizinische Beratung, Diagnose, Behandlungsempfehlung oder Anlageberatung dar.

Klinische Studie

ReDS-Guided Decongestion in Acute Heart Failure (ReDS-LATAM HF)

NCT: NCT07600398 · ACTIVE_NOT_RECRUITING

NCT-IDNCT07600398
Medizinische Daten: StatusACTIVE_NOT_RECRUITING
Startdatum2026-05-01
Abschluss2027-06-01
SponsorInstituto Cardiovascular de Buenos Aires (OTHER)
First posted
Last updated

Kurzzusammenfassung

Heart failure (HF) is a leading cause of hospitalization, with high rates of early readmission largely driven by residual congestion at discharge. Conventional methods to assess congestion are often imprecise and may fail to guide optimal decongestive therapy. Remote Dielectric Sensing (ReDS) is a non-invasive technology that provides a rapid and objective estimate of lung fluid content. This study aims to evaluate whether a ReDS-guided decongestion strategy improves clinical outcomes compared with standard care in patients hospitalized for acute heart failure. In this randomized controlled trial, patients will be assigned 1:1 to a ReDS-guided strategy or standard care. ReDS measurements will be performed in both groups but will only guide treatment in the intervention arm. The primary endpoint is a composite of all-cause mortality, heart failure rehospitalization, or unplanned HF visit within 30 (±5) days after discharge.

Offizielle Quelle

Auf ClinicalTrials.gov ansehen →

Daten aus der ClinicalTrials.gov-API. Den aktuellsten Status finden Sie im offiziellen Eintrag.

↑